《新股消息》梅斯健康(02415.HK)公開發售下限定價9.1元 一手中籤率20%
中國在線專業醫師平台梅斯健康(02415.HK)公布招股結果,每股發售價定為9.1元,為招股價範圍(9.1至10.16元)下限定價,香港公開發售部分錄得超額認購約8.85倍。每手250股,一手中籤率20%,認購8手可穩獲一手。該股明日(27日)掛牌。聯席保薦人為中金及麥格理。
公司引入六名基石投資者,包括Harvest、廣發証券(01776.HK)旗下廣發全球、安吉國融、安吉交投、安吉創投及七彩靈峰,共認購3,450.48萬股,佔全球發售完成後公司股本約5.68%。
此外,公司上市料淨集資約5.38億元,當中約45%用於業務擴張;約35%用於進一步的技術開發;約15%用於潛在投資及收購或與能夠與公司業務產生協同效應的公司建立戰略聯盟;及5%用作營運資金及一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.